Answers are grounded in this paper and cite their sources.
Abstract ID 127349 Poster Board 460 Poly(ADP-ribose) polymerase 1 (PARP1), a DNA repair nuclear enzyme, is over-expressed in ovarian, breast, and prostate cancers and its targeted inhibition by small molecules (e.g., olaparib, rucaparib, niraparib, and talazoparib) has been successfully utilized in clinic. Unfortunately, frequent use of PARP inhibitors in clinics has also resulted in patients developing rapid resistance via various mechanisms. Therefore, novel class of PARP1 inhibitory scaffold that is potent and selective is urgently needed to circumvent this problem. In this study, a novel nicotinamide mimicking pharmacophore, 7-aminoquinolin-2(1H)-one, has been identified. With the aid of molecular modeling, we have designed and synthesized several derivatives as PARP1 inhibitors utilizing acid-amine coupling and reductive alkylation protocol. A recombinant in vitro PARP1 enzyme assay revealed that developed inhibitors are potent and selective and can potentially exert favorable BRCA-driven cytotoxicity profile in ovarian and breast cancer cell lines. This effort could potentially lead to development of PARP1-targeted drugs with enhanced therapeutic benefits.
No takes yet. Share an insight, caveat, or question.
Pathak et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: